EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials. The results of mechanistic studies suggest that the benefits of SGLT2i on diastolic heart failure are independent of their glycosuric actions and may still be present in anuric subjects. Despite the significance of HFpEF in patients with CKD, patients with advanced kidney disease have been excluded from studies investigating anti-heart failure drugs. The effects of SGLT2i in patients under maintenance dialysis are largely unknown. Past pharmacokinetics and pharmacodynamics studies on empagliflozin in patients with end-stage renal disease (ESRD) demonstrated that the use of empagliflozin in patients with ESRD seemed safe, yet its efficacy remains to be explored.

NCT Number	NCT06249945
Lead Sponsor	National Taiwan University Hospital Collaborators: Shin Kong Wu Ho-Su Memorial Hospital
Conditions	Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
Enrollment	150 participants
Start Date	2024-03-05
Primary Completion	2027-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-12-16